Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980468 | 0.94 | TP53 (0.46) | PGRSMN1; SMN2CYP11B1CYP11B2TP53 | |
| SCHEMBL6977638 | 0.93 | PGR (0.59) | PGRCYP11B1CYP11B2MAPK8MAPK9 | |
| SCHEMBL6975394 | 0.93 | SMN1; SMN2 (0.43) | PGRSMN1; SMN2CYP11B1CYP11B2TP53 | |
| SCHEMBL6982038 | 0.92 | PGR (0.52) | PGRCYP11B1CYP11B2MAPK8MAPK9 | |
| SCHEMBL6978742 | 0.91 | SMN1; SMN2 (0.44) | PGRSMN1; SMN2CYP11B1CYP11B2TP53 | |
| SCHEMBL6982742 | 0.91 | PGR (0.41) | PGRSMN1; SMN2CYP11B1CYP11B2TP53 | |
| SCHEMBL6983308 | 0.90 | CYP11B1 (0.52) | PGRCYP11B1CYP11B2TP53P2RX4 | |
| SCHEMBL6981339 | 0.89 | CYP11B1 (0.49) | PGRCYP11B1CYP11B2MAPK8MAPK9 | |
| SCHEMBL6979436 | 0.88 | CYP11B1 (0.52) | PGRCYP11B1CYP11B2 | |
| SCHEMBL6981838 | 0.88 | PGR (0.52) | PGRCYP11B1CYP11B2MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | PGR 4288/4885SMN1; SMN2 2735/4885CYP11B1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.